Literature DB >> 30553404

The endocannabinoid system: Overview of an emerging multi-faceted therapeutic target.

Dipanjan Chanda1, Dietbert Neumann2, Jan F C Glatz3.   

Abstract

The endocannabinoids anandamide (AEA) and 2-arachidonoylglyerol (2-AG) are endogenous lipid mediators that exert protective roles in pathophysiological conditions, including cardiovascular diseases. In this brief review, we provide a conceptual framework linking endocannabinoid signaling to the control of the cellular and molecular hallmarks, and categorize the key components of endocannabinoid signaling that may serve as targets for novel therapeutics. The emerging picture not only reinforces endocannabinoids as potent regulators of cellular metabolism but also reveals that endocannabinoid signaling is mechanistically more complex and diverse than originally thought.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  2-arachidonoylglyerol; Anandamide; Ccardiovascular disease; Insulin resistance

Mesh:

Substances:

Year:  2018        PMID: 30553404     DOI: 10.1016/j.plefa.2018.11.016

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  18 in total

1.  Symmetrically substituted dichlorophenes inhibit N-acyl-phosphatidylethanolamine phospholipase D.

Authors:  Geetika Aggarwal; Jonah E Zarrow; Zahra Mashhadi; C Robb Flynn; Paige Vinson; C David Weaver; Sean S Davies
Journal:  J Biol Chem       Date:  2020-04-13       Impact factor: 5.157

2.  Endocannabinoids as potential biomarkers: It's all about pre-analytics.

Authors:  Daniel Kratz; Dominique Thomas; Robert Gurke
Journal:  J Mass Spectrom Adv Clin Lab       Date:  2021-11-10

3.  The Endocannabinoid System May Modulate Sleep Disorders in Aging.

Authors:  Eric Murillo-Rodríguez; Henning Budde; André Barciela Veras; Nuno Barbosa Rocha; Diogo Telles-Correia; Diogo Monteiro; Luis Cid; Tetsuya Yamamoto; Sérgio Machado; Pablo Torterolo
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

4.  Antitumor Activity of Abnormal Cannabidiol and Its Analog O-1602 in Taxol-Resistant Preclinical Models of Breast Cancer.

Authors:  Andrea Tomko; Lauren O'Leary; Hilary Trask; John C Achenbach; Steven R Hall; Kerry B Goralski; Lee D Ellis; Denis J Dupré
Journal:  Front Pharmacol       Date:  2019-09-27       Impact factor: 5.810

5.  Pharmacokinetics of Sativex® in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders.

Authors:  María Fernández-Trapero; Carmen Pérez-Díaz; Francisco Espejo-Porras; Eva de Lago; Javier Fernández-Ruiz
Journal:  Biomolecules       Date:  2020-02-11

Review 6.  Retinol-binding protein 2 (RBP2): biology and pathobiology.

Authors:  William S Blaner; Pierre-Jacques Brun; Rossana M Calderon; Marcin Golczak
Journal:  Crit Rev Biochem Mol Biol       Date:  2020-05-28       Impact factor: 8.250

7.  Cannabidiol Regulates the Expression of Keratinocyte Proteins Involved in the Inflammation Process through Transcriptional Regulation.

Authors:  Anna Jastrząb; Agnieszka Gęgotek; Elżbieta Skrzydlewska
Journal:  Cells       Date:  2019-08-03       Impact factor: 6.600

8.  Urine Endocannabinoids as Novel Non-Invasive Biomarkers for Bladder Cancer at Early Stage.

Authors:  Riccardo Vago; Alessandro Ravelli; Arianna Bettiga; Silvana Casati; Giovanni Lavorgna; Fabio Benigni; Andrea Salonia; Francesco Montorsi; Marica Orioli; Pierangela Ciuffreda; Roberta Ottria
Journal:  Cancers (Basel)       Date:  2020-04-03       Impact factor: 6.639

9.  Retinol-binding protein 2 (RBP2) binds monoacylglycerols and modulates gut endocrine signaling and body weight.

Authors:  Seung-Ah Lee; Kryscilla Jian Zhang Yang; Pierre-Jacques Brun; Josie A Silvaroli; Jason J Yuen; Igor Shmarakov; Hongfeng Jiang; Jun B Feranil; Xueting Li; Atreju I Lackey; Wojciech Krężel; Rudolph L Leibel; Jenny Libien; Judith Storch; Marcin Golczak; William S Blaner
Journal:  Sci Adv       Date:  2020-03-11       Impact factor: 14.136

Review 10.  Endocannabinoid Receptors in the CNS: Potential Drug Targets for the Prevention and Treatment of Neurologic and Psychiatric Disorders.

Authors:  José Antonio Estrada; Irazú Contreras
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.